All In Biotech

Drug Trial Radar · NCT02724020

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy

Last checked: Nov 19, 2026Latest source record: Nov 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

96

Actual

Start

Jun 30, 2016

Primary completion

Feb 3, 2020

Study completion Oct 13, 2020

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Mar 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with metastatic clear-cell renal cell carcinoma (mccRCC) that have progressed on vascular endothelial growth factor (VEGF)-targeted therapy.

Conditions

  • Clear-cell Metastatic Renal Cell Carcinoma

Interventions

  • EverolimusDrug

    Everolimus capsules.

  • MLN0128Drug

    MLN0128 capsules.

  • MLN1117Drug

    MLN1117 capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From first dose of study drug up to disease progression or death, assessed up to 43 months

Locations

36 sites in 8 countries. Site status is shown where the registry gives one.

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • Florida Cancer Specialists-Broadway

    Venice, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Hackensack University Medical Center PARTNER

    Hackensack, New Jersey

  • The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital

    Columbus, Ohio

  • Tennessee Oncology

    Nashville, Tennessee

  • The Center for Cancer and Blood Disorders

    Weatherford, Texas

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada

  • McMaster University

    Hamilton, Ontario, Canada

  • Fakultni nemocnice u sv. Anny v Brne

    Brno, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Groupe Hospitalier Saint Andre - Hopital Saint Andre

    Bordeaux, Aquitaine, France

  • ICL-Alexis Vautrin, Departement dOncologie Medicale

    Vandœuvre-lès-Nancy, Meurthe Et Moselle, France

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, Paris, France

  • Institut de Cancerologie de l'Ouest Paul Papin

    Angers, Pays de la Loire Region, France

  • Clinique Victor Hugo - Centre Jean Bernard

    Le Mans, Sarthe, France

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi

    Bologna, Italy

  • Istituto Nazionale Tumori Fondazione G. Pascale

    Naples, Italy

  • IOV - Istituto Oncologico Veneto IRCCS

    Padova, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Beskidzkie Centrum Onkologii im.Jana Pawla II

    Bielsko-Biala, Poland

  • Instytut MSF, Ulica Pilota Stanislawa Wigury 19

    Lodz, Poland

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, Spain

  • MD Anderson Cancer Centre

    Madrid, Spain

  • Hospital Universitario Ramon Y Cajal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Royal Devon and Exeter Hospital (Wonford)

    Exeter, Devon, United Kingdom

  • Lancashire Teaching Hospitals NHS Foundation Trust

    Blackburn, England, United Kingdom

  • Barts Hospital

    London, Greater London, United Kingdom

  • The Christie

    Manchester, Greater Manchester, United Kingdom

  • Velindre Cancer Centre

    Cardiff, South Glamorgan, United Kingdom

  • Royal Surrey County Hospital

    Guildford, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.